Tempus AI's stock surged 7.34% during intraday trading on Wednesday.

The significant price movement followed the company's announcement of the launch of HRD-RNA, a pan-cancer artificial intelligence algorithm designed to identify homologous recombination deficiency (HRD). The tool aims to predict which solid tumor patients may respond to platinum-based chemotherapy or PARP inhibitors.

Tempus AI cited a real-world validation study in metastatic pancreatic cancer, which indicated that patients identified as HRD-RNA-positive and treated with first-line platinum regimens showed a reduced mortality risk compared to those on non-platinum therapies. The full supporting data for this study are expected to be published later this year.